Vitamin d derivative tested as chemo booster for pancreatic cancer

NCT ID NCT04054362

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small pilot study tested whether adding a vitamin D-like drug called paricalcitol to standard chemotherapy could help people with advanced pancreatic cancer that had stopped responding. 27 patients received chemotherapy first, then paricalcitol was added if their disease stabilized or worsened. The goal was to see if this combination could improve outcomes, but the study was very small and early-stage, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
paricalcitol (a form of vitamin D) added to chemotherapy (paclitaxel protein bound, gemcitabine, with or without cisplatin)
What this could lead to
If it works, this could point toward a way to improve chemotherapy response in advanced pancreatic cancer.
What could go wrong
This is a very small, early-phase pilot study with only 27 participants. It may not show clear benefit, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Barts Health NHS Trust

    London, London, Greater, EC1M 6BQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.